Table 4.4.
PM-19 dose response for the mice infected with HSV-2
| Compound | Dose (mg/kg−1/kg−1) | Number of survivors/total | Survival days |
|---|---|---|---|
| Experiment 1 | |||
| No treatment | 0/24 (0)a | 6.83 ± 0.46 (0)a | |
| PM-19 | 0.03 (on days 0–2) | 0/12 (0) | 6.83 ± 0.42 (0) |
| 0.1 (on days 0–2) | 2/12 (17) | 8.00 ± 1.03 (17) | |
| 0.3 (on days 0–2) | 7/12 (58)**b | 11.50 ± 0.94 (68)**b | |
| 1.0 (on days 0–2) | 9/12 (75)** | 12.08 ± 1.02 (77)** | |
| ACV | 25.0 (on days 0–5) | 2/12 (17) | 7.64 ± 1.22 (12) |
| 50.0 (on days 0–5) | 2/12 (17) | 9.08 ± 0.84 (33)* | |
| Experiment 2 | |||
| No treatment | 2/24 (8) | 7.13 ± 0.47 (0) | |
| PM-19 | 1.0 (on days 0–2) | 9/12 (75)** | 13.08 ± 0.48 (84)** |
| 2.5 (on days 0–2) | 8/12 (67)** | 11.50 ± 1.07 (61)** | |
| 5.0 (on days 0–2) | 7/12 (58)** | 11.40 ± 1.02 (60)** | |
| 10.0 (on days 0–2) | 9/12 (75)** | 12.50 ± 0.87 (75)** | |
| 25.0 (on days 0–2) | 11/12 (92)** | 14.00 ± 0.00 (97)** | |
| 50.0 (on days 0–2) | 9/12 (75)** | 12.33 ± 0.92 (73)** | |
| ACV | 25.0 (on days 0–2) | 0/12 (0) | 7.92 ± 0.78 (11) |
| 50.0 (on days 0–2) | 0/12 (0) | 7.33 ± 0.38 (3) | |
| 100.0 (on days 0–2) | 1/12 (8) | 3.85 ± 1.54 (−50) | |
Mice were treated i.p. with indicated doses of the test compounds once daily from day 0 (immediately after infection) until day 2 or 5 after i.p. infection with HSV-2 (2.8 × 102 pfu)
aNumber in parenthesis indicates the percentage of mice that were still alive on day 14 after infection
bSignificantly different from corresponding tumor control group (*p < 0.05; **p < 0.01)